Axcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Long COVID, OHE and NASH Clinical Trials
Retrieved on:
Wednesday, November 10, 2021
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, American Association, CTA, Enrollment, Therapy, Director, Regulation Fair Disclosure, D, Non-alcoholic fatty liver disease, COVID-19, Â, American Journal, Disclosure, Risk, Laurent, University of Oxford, Safety, Fatty liver disease, Recurrence, Compte rendu, MHRA, PASC, Degenerative disease, Trial of the century, University, Association, NASH, Research, Annual general meeting, EMM, Medicines and Healthcare products Regulatory Agency, The American Journal of Gastroenterology, Patient, FDA, Emms, Health care, Private Securities Litigation Reform Act, Inflammation, AASLD, United, Program, Fatigue, Metabolism, SEC, Science, Biological activity, Institute of Liver and Biliary Sciences, OHE, Board, Homeostasis, Ethics committee, Fibrosis, Regulation, IND, Pharmaceutical industry, Dietary supplement
The third quarter of 2021 was a time in which Axcella focused heavily on both execution and expansion, said Bill Hinshaw, President and Chief Executive Officer of Axcella.
Key Points:
- The third quarter of 2021 was a time in which Axcella focused heavily on both execution and expansion, said Bill Hinshaw, President and Chief Executive Officer of Axcella.
- Progressed Screening and Enrollment in EMMPOWER and EMMPACT Clinical Trials: Patient screening and enrollment continues in Axcellas recently initiated EMMPOWER Phase 2 clinical trial in overt hepatic encephalopathy (OHE) and EMMPACT Phase 2b clinical trial in nonalcoholic steatohepatitis (NASH).
- Published AXA1125 Data in The American Journal of Gastroenterology: The American Journal of Gastroenterology recently published results from Axcellas AXA1125-003 clinical study.
- The companys unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials.